Eli Lilly Earnings Surge as Obesity Drug Rivalry Reshapes Health Sector

The health care sector experienced a volatile trading session as the race for dominance in the obesity-drug market created distinct market leaders and laggards. Eli Lilly shares rallied sharply after the manufacturer of the Zepbound weight-control treatment reported a 43% increase in quarterly revenue, a figure that significantly surpassed Wall Street expectations.

Market Winners and Laggards

While Lilly thrived, its primary Danish competitor, Novo Nordisk, saw its shares continue a downward trend. The decline followed a company warning that increased price competition in the U.S. for its Ozempic and Wegovy treatments would likely constrain sales growth for the remainder of the year. Conversely, Amgen shares climbed as strong demand for its asthma therapies offset investor frustration over development delays for the firm's own weight-loss candidates.

The medical technology and equipment segment also showed mixed results. GE Healthcare shares rose after the company reported revenue growth across its imaging and diagnostic divisions. However, Boston Scientific shares fell sharply after the medical-device manufacturer issued first-quarter earnings and sales growth forecasts that lagged behind analyst projections. Even AbbVie saw its stock price decline, despite reporting earnings and a growth outlook that beat consensus targets.